Revenue Cycle Insider

Path/Lab Coding:

Beware Payer Bundling for Multiple STI NAAT Tests

Know when payer policy overrides CPT®, NCCI rules. Consider the following scenario, common to laboratories across the country: A clinician suspects their patient has a sexually transmitted infection (STI) and orders testing for Chlamydia trachomatis, Neisseria gonorrhoeae, and Trichomonas vaginalis to try to identify the infectious agent responsible. Your lab performs nucleic acid amplification tests (NAAT) for each of those organisms, which you bill [...]
You’ve reached your limit of free articles. Already a subscriber? Log in.
Not a subscriber? Subscribe today to continue reading this article. Plus, you’ll get:
  • Simple explanations of current healthcare regulations and payer programs
  • Real-world reporting scenarios solved by our expert coders
  • Industry news, such as MAC and RAC activities, the OIG Work Plan, and CERT reports
  • Instant access to every article ever published in Revenue Cycle Insider
  • 6 annual AAPC-approved CEUs
  • The latest updates for CPT®, ICD-10-CM, HCPCS Level II, NCCI edits, modifiers, compliance, technology, practice management, and more

Other Articles of

October 2025

View All